AVITA Medical corrects Q1 revenue to $10.6M, net loss $9.2M in 8-K/A amendment

AVITA Medical, Inc.

2023-Q1 EPS reported $0.37 revenue$10,550,000

Revenue $10.6M (U.S. Dollars); net loss $9.2M, $0.37 per share for quarter ended March 31, 2023.
Original 8-K transcript erroneously included extraneous tabular data in Australian Dollars; this amendment corrects that error.
Further details available in Form 10-Q filed May 11, 2023.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AVITA Medical, Inc. reported fiscal quarter ended March 31, 2023 results: revenue $10.6 million, net income $9.2 million, EPS $0.37 per share.

Period: fiscal quarter ended March 31, 2023
Revenue: $10.6 million
Net income: $9.2 million
EPS: $0.37 per share
Result: reported results

Exact text from the filing

Item 2.02. Results of Operations and Financial Condition. On May 12, 2023, AVITA Medical, Inc. (the “Company”) furnished a Current Report on Form 8-K (the “Original Form 8-K”) with a transcript of the Company’s May 11, 2023 conference call discussing the Company’s financial results for its fiscal quarter ended March 31, 2023 as Exhibit 99.2. Exhibit 99.2 to the Original Form 8-K inadvertently included extraneous tabular information from S&P Global Market Intelligence, including financial results and consensus data for the quarter ended March 31, 2023 in Australian Dollars. The Company’s actual results are reported in U.S. Dollars and included $10.6 million in revenue and a net loss of $9.2 million, or $0.37 per share.

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-145360

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.